Parr Biotechnology

Parr Biotechnology (also known as Huapu Bio) is a clinical-stage biopharmaceutical company specializing in the development of novel CpG-adjuvanted vaccines and tumor immunotherapies. Leveraging its proprietary CpG ODN technology platform, the company designs next-generation adjuvants that stimulate Toll-like receptor 9 (TLR9) to elicit robust Th1-biased immune responses. Parr Biotechnology's pipeline includes advanced vaccine candidates for influenza (HP-3001), shingles (HP-2001), and hepatitis B (HP-2002), alongside oncology candidates like the TLR9 agonist HP007 and the bispecific fusion protein FS-8002 targeting VEGF and TGF-beta. The company operates state-of-the-art R&D and GMP manufacturing facilities in Shijiazhuang and Shanghai, China, to support its clinical programs and commercial-scale adjuvant production.